Skip to main content
Clinical Trials/NCT03820882
NCT03820882
Completed
Not Applicable

Catfish Flow Restoration Device for Thrombectomy Revascularisation of Large Vessel Occlusions in Acute Ischemic Stroke: a Randomised, Parallel-group, Non-inferiority Trial

Ministry of Science and Technology of the People´s Republic of China1 site in 1 country238 target enrollmentMarch 3, 2019

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Acute Ischemic Stroke
Sponsor
Ministry of Science and Technology of the People´s Republic of China
Enrollment
238
Locations
1
Primary Endpoint
Instant recanalization rate (mTICI 2b-3) of target vessel after the procedure
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

The study is a randomized, prospective, parallel-group, multicenter, open-label, non-inferiority trial. Patients are randomized 1 : 1 to either stent retriever(Catfish) or Solitaire for endovascular therapy for acute ischemic stroke. The study aims to evaluate the benefit and safety of stent retriever(Catfish) for acute ischemic stroke therapy, as compared to Solitaire FR.

Detailed Description

The main objective is to determine whether stent retriever(Catfish) will have non-inferior successful recanalization rate compared to Solitaire in patients with acute ischemic stroke caused by large vessel occlusion. The secondary objectives is to verify whether there is significant differences in time from artery puncture to successful recanalization (mTICI 2b or greater), NIHSS score at 24 hours and at 7 days or discharge if earlier, good clinical outcomes at 90 days (defined as mRS score ≤2) between stent retriever(Catfish) and Solitaire in patients with acute ischemic stroke caused by large vessel occlusion. The third objectives is to compare the rate of symptomatic intracranial hemorrhage, serious adverse event(SAE), all cause of mortality with 90 days after operation, between stent retriever (Catfish) and Solitaire in patients with acute ischemic stroke due to large vessel occlusion.

Registry
clinicaltrials.gov
Start Date
March 3, 2019
End Date
June 5, 2021
Last Updated
3 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Ministry of Science and Technology of the People´s Republic of China
Responsible Party
Principal Investigator
Principal Investigator

Zhongrong Miao

Director, Head of Neurointerventional, Principal Investigator, Clinical Professor

Ministry of Science and Technology of the People´s Republic of China

Eligibility Criteria

Inclusion Criteria

  • 18≤ages≤80;
  • mRS score must lower than 2 Pre-AIS(acute ischemic stroke).
  • Baseline NIHSS score obtained prior to randomization must be between 8 and 25;
  • Symptoms and signs in accordance with Large vessel occlusion, confirmed by CTA(CT angiogram)/MRA(magnetic resonance angiography )/DSA;
  • Patient treatable within 8 hours of symptom onset (symptoms onset is defined as point in time the patient was last seen well (at baseline)) can accept the complete femoral artery puncture;
  • Baseline Alberta stroke program early CT score (ASPECTS) or posterior circulation Alberta stroke program early CT score (pc-ASPECTS)≥ 6 on Computed tomography (CT) or magnetic resonance imaging(MRI).
  • The patient or relative give written informed consent.

Exclusion Criteria

  • History of stroke in past 3 months.
  • Presumed septic embolus, or suspicion of bacterial endocarditis.
  • Evidence of tortuosity of cervical vessels precluding device delivery/deployment;
  • Hypertension (Systolic blood pressure(SBP)\>185 mmHg or diastolic blood pressure(DBP)\>110 mm Hg) after using drug;
  • Platelet count\<30,000/μL and use of Novel Anticoagulant with International Normalized Ratio(INR)\>3.0;
  • Random blood glucose of\<2.7mmol/L or\>22.2mmol/L;
  • Patients with heart or lung or liver or renal failure or other sever disease (intracranial tumors, cerebral arteriovenous malformation (AVM), systemic infection, active disseminated intravascular coagulation, history of sever psychosis);
  • Patients with Dementia or psychiatric disease that would confound the neurological or functional evaluations.
  • Anticipated life expectancy of less than 6 months;
  • Known serious sensitivity to contrast medium and nitinol metal;

Outcomes

Primary Outcomes

Instant recanalization rate (mTICI 2b-3) of target vessel after the procedure

Time Frame: immediate

Successful recanalization is defined as modified Thrombolysis In Cerebral Ischemia scale 2b or 3. And it is evaluated by DSA(digital subtraction angiography ) intraoperative immediately in both treatment groups

Secondary Outcomes

  • Time to achieve recanalization(intraprocedure immediate)
  • all cause of mortality within 90±14 days after procedure(90±14 days)
  • NIHSS score at 7±1 days or discharge(7±1 days)
  • NIHSS score at 24±2 hours(24±2 hours)
  • proportion of patients who got a mRS 0-2 at 90±14 days(90±14 days)
  • serious adverse event(SAE) within 90±14 days after procedure(90±14 days)
  • symptomatic intracranial hemorrhage after procedure(24±2 hours)

Study Sites (1)

Loading locations...

Similar Trials